TNXP Fact Sheet May 2012

TONIX Quick Facts Trading Symbol: TNXP:OTCQB Stock Price (4/30/12): $1.60 Shares Outstanding: 34.3 Million Market Capitalization: $54.9 Million Fiscal Year End: December 31 Stock Transfer Agent: vStock Transfer SEC Counsel: Sichenzia Ross Friedman FACT SHEET – May 1, 2012 Ference LLP Auditors: EisnerAmper LLP IR Contact: Benjamin Selzer (212) 980‐9155 x106 Website: www.tonixpharma.com Corporate Overview TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system (CNS). The company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX reformulates and repurposes known pharmaceutical agents to develop products with optimal safety, efficacy and predictability. TONIX also intends to commercialize generic products through its wholly‐owned subsidiary, Krele LLC. Focus on Fibromyalgia and Post‐Traumatic Stress Disorder – Large Markets with Unmet Need TONIX is focusing its initial product development efforts on fibromyalgia syndrome (FM) and post‐traumatic stress disorder (PTSD), two CNS conditions with related, often debilitating symptoms that can affect daily living. FM, which affects about 5 million Americans, is characterized by chronic widespread pain and concurrent symptoms including sleep disturbance, fatigue and decrease in physical and cognitive function. PTSD is a psychiatric disorder that can appear following a traumatic experience, and has both combat and civilian forms. Approximately 3.5% of the U.S. adult population will have suffered from PTSD within the past 12 months. Sleep disturbances including nightmares and insomnia are core features of FM and PTSD. FM and PTSD share several common symptoms, and some patients are believed to suffer from both. Novel Formulation Technology Applied to Known Ingredients = Better Drugs The company’s lead product candidates for these indications, TNX‐102 for FM and TNX‐105 for PTSD, are novel dosage oral formulations of cyclobenzaprine, the active ingredient in two U.S. FDA‐ approved muscle relaxants. TONIX is applying its patent‐protected formulation technology to improve absorption, drug clearance and peak blood levels relative to currently marketed cyclobenzaprine products. In a Phase 2a study, very low dose cyclobenzaprine (VLDC) administered at bedtime has been demonstrated to improve core FM symptoms, such as pain, tenderness, fatigue and depression. Strategy to Reduce Development Risk and Streamline Regulatory Path A significant body of data on cyclobenzaprine, the active ingredient in the company’s drugs, is already in the public domain and as the result of previously approved NDAs for marketed products. TONIX anticipate seeking approval of TNX‐102 and TNX‐105 through the NDA process under Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act (FFDCA). This approach would allow TONIX to reference existing data for its NDA filings, and may enable its product candidates to advance through development and the regulatory process on a less costly, shorter pathway than is typical for pharmaceutical products based on novel active ingredients. TONIX PHARMACEUTICALS, INC. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022PHONE: (212) 980‐9155 FAX: (212) 923‐5700 www.tonixpharma.com

Robust Product Pipeline with Near‐term Milestones Product Indication Status TNX‐102 Fibromyalgia • Very low dose cyclobenzaprine in novel formulation • Phase 2a successfully completed • Completing formulation development • First of two pivotal trials expected to begin Q1 2013 TNX‐105 Post‐Traumatic Stress • Low dose cyclobenzaprine in novel formulation Disorder • Will leverage data from TNX‐102 PK trial • Pivotal trials anticipated to start 2013 • Applying for Department of Defense funding TNX‐201 Headache • NDA to be filed for existing DESI product • Potentially shortened process for FDA approval • DESI to NDA switch products enjoy mandated exclusivity TNX‐301 Alcoholism • US patent allowed • Potential for government funding Experienced Leadership Title Experience Seth Lederman, MD CEO & Chairman • Co‐founder, Vela, Targent, Validus & Fontus Benjamin A. Selzer COO • Aton, Reliant, investment banking Leland J. Gershell, MD, PhD CFO • Cowen, Apothecary Capital, Favus Research, Madison Williams Bruce L. Daugherty, PhD, MBA Senior Director of • Merck, Roche Institute Drug Development Stuart Davidson Director • Managing Partner, Labrador Ventures • Former CEO, Alkermes & Combion Patrick P. Grace Director • Managing Partner, Apollo Philanthropy Partners, LLC Donald W. Landry, MD, PhD Director • Columbia University, Chair of Medicine Ernest Mario, PhD Director • Former CEO, Glaxo, Alza & Reliant Charles Mather Director • Managing Director, Janney Capital Markets John Rhodea Director • Former Partner, Booz Allen & Hamilton Recent News Events http://ir.stockpr.com/tonixpharma/press‐releases TONIX PHARMACEUTICALS, INC. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022PHONE: (212) 980‐9155 FAX: (212) 923‐5700 www.tonixpharma.com

TNXP Fact Sheet May 2012

by ProActive Capital Resources Group

Accessibility

Categories

Upload Details

Usage Rights

1 Embed 92

Statistics

TNXP Fact Sheet May 2012 Document Transcript